Berdazimer Sodium

Summary

Berdazimer Sodium (CHEMBL4298064) is an approved small molecule; indicated across 4 conditions including molluscum contagiosum and acne.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 17

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298064
Name	Berdazimer Sodium
Type	Small molecule
Max phase	4

Also known as: Berdazimer sodium, Berdazimere sodique, Berdazimero de sodio, NVN-1000, Nvn1000, NVN1000, Sb-204, Sb204, Sb206, Sb208, Zelsuvmi, BERDAZIMER SODIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
molluscum contagiosum	4	MONDO:0005855	MONDO:0005855
acne	3	MONDO:0011438	EFO:0003894
anogenital human papillomavirus infection	2	MONDO:0005647	EFO:0007147
tinea pedis	2	MONDO:0005984	EFO:0007512

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
PHASE3	6
PHASE2	5
PHASE1	5
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02667444	PHASE3	COMPLETED	P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne
NCT02672332	PHASE3	COMPLETED	P3 Study in Acne Comparing Once Daily SB204 and Vehicle
NCT02798120	PHASE3	COMPLETED	P3 Long Term Safety Study of Once Daily SB204 in Acne
NCT03927703	PHASE3	COMPLETED	A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC
NCT03927716	PHASE3	COMPLETED	A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)
NCT04535531	PHASE3	COMPLETED	A Phase 3 Molluscum Contagiosum Efficacy and Safety Study
NCT01556698	PHASE1/PHASE2	COMPLETED	Study of NVN1000 Topical Gel and Topical Gel Vehicle in the Treatment of Moderate to Severe Acne Vulgaris
NCT01844752	PHASE2	COMPLETED	A Phase 2, 3 Arm Study of NVN1000 Gel and Vehicle Gel in Subjects With Acne
NCT02242760	PHASE2	COMPLETED	P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris
NCT02462187	PHASE2	COMPLETED	Topical NVN1000 for the Treatment of External Genital and Perianal Warts
NCT02860052	PHASE2	COMPLETED	SB208 for the Treatment of Tinea Pedis
NCT03436615	PHASE2	COMPLETED	A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
NCT01844739	PHASE1	COMPLETED	A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel
NCT02164084	PHASE1	COMPLETED	A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris
NCT02250430	PHASE1	COMPLETED	A Phase 1 Study Assessing Local Cutaneous Effects of SB204
NCT02581072	PHASE1	COMPLETED	A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204
NCT02801903	PHASE1	COMPLETED	Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).